Jan Stenvang

Jan Stenvang

Associate Professor

  • Molecular and Cellular Pharmacology

    Jagtvej 160

    2100 København Ø


  1. Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA)

    Stenvang, Jan, Pfundheller, H. M. & Lykkesfeldt, A. E., 2004, In: Oligonucleotides. 14, 2, p. 147-56 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. LNA-antisense rivals siRNA for gene silencing

    Stenvang, Jan & Wengel, J., Mar 2004, In: Current Opinion in Drug Discovery & Development. 7, 2, p. 188-94 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology

    Stenvang, Jan, Sørensen, M. D. & Wengel, J., 2004, In: Oligonucleotides. 14, 2, p. 130-46 17 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA)

    Vollmer, J., Uhlmann, E., Stenvang, Jan, Schetter, C., Jurk, M., Wader, T., Wüllner, M. & Krieg, A. M., 2004, In: Oligonucleotides. 14, 1, p. 23-31 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment.

    Christensen, G. L., Stenvang, Jan, Fog, C. K., Christensen, I. J. & Lykkesfeldt, A. E., 2004, In: Breast Cancer Research and Treatment. p. 53–63

    Research output: Contribution to journalJournal articleResearchpeer-review

ID: 12922